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Circulating interleukin-6 and tumor necrosis factor receptor-1 predict 
resistance to therapy of typhoidal salmonellosis  
 
INTRODUCTION 
Typhoid fever, encountered in all parts of the 
world, is nowadays primarily found in countries 
where sanitary conditions are poor. It is considered 
to be one of the most important and under-reported 
diseases in the developing world. In some areas, it 
has been estimated that typhoid fever is responsible 
for 2 to 5% of all deaths. Hospital case fatalities 
are still high (1 to 30%), in many parts of the 
developing world1. In the US, the incidence was 
400 cases/year, mostly among travelers2. In Egypt, 
Crump et al.3 estimated the incidence of typhoid 
fever to be 13/100000 persons. 
 S. typhi, the etiologic organism of typhoid 
fever, is similar to other Salmonellae in that it is a 
gram-negative, flagellated, non-capsulated, non- 
 
sporulating, facultative anaerobic bacillus. It has a 
somatic (O) antigen (oligosaccharide), flagellar (H) 
antigen (protein), and an envelop (K) antigen 
(polysaccharide); and has a lipopolysaccharide 
macro-molecular complex called endotoxin that 
forms the outer portion of the cell wall4. 
Cellular immune response, a major 
characteristic of typhoid fever, entails activation of 
macrophages. Phagocytosis is a major host defense 
mechanism, and substances released from 
macrophages, including cytokines, probably have a 
significant role in the pathogenesis of the disease5. 
So this work aimed to study the changes in the 
levels of IL-6 and TNF-R1, as well as the effect of 
these changes on the clinical course of children 
suffering from typhoid fever. 
Original article 
Background: Typhoid fever, a food-borne disease caused by salmonella 
species, is a worldwide prevalent disease. In endemic areas, children are at 
highest risk owing to weaning from passively acquired maternal antibody 
and lack of acquired immunity. Several studies have been done to clarify the 
pathogenesis and underlying immune aspects of typhoid fever. Objective: 
Study the changes of some proinflammatory cytokines in plasma of children 
with typhoid fever. Study design: Thirty consecutive children admitted to 
Zagazig Fever Hospital with proven diagnosis of typhoid fever were 
included in the study. They were 20 males and 10 females, of ages ranging 
from 3 to 13 years. In addition, 10 age and sex matched healthy children 
served as a control group. A verbal consent was obtained from parent(s) of 
each child before inclusion to the study. All children were subjected to 
history taking, clinical examination, and routine investigations (CBC, ESR, 
CRP, Widal test and stool culture), as well as determination of serum 
interleukin-6 (IL-6) and tumor necrosis factor receptor-1 (TNF-R1), before 
and 5 days after start of treatment (for patients). Results: Twenty patients 
(66.7%) were responsive to therapy and 10 patients (33.3%) were resistant. 
Toxic look, constipation, high fever, splenomegaly, increased CRP and ESR 
were significantly presented in patients who displayed resistance to drug 
therapy. Both IL-6 and TNF-R1 plasma levels were significantly higher in 
patients than in control children, and in resistant cases than in responsive 
cases (before and 5 days after treatment). ESR and S. typhi H agglutination 
titre correlated significantly with plasma levels of IL-6 and TNF-R1, 
whereas S. typhi O agglutination titre and total leucocytic count did not. 
Conclusion: patients with typhoid fever resistant to combined therapy with 
chloramphenicol and co-trimoxazole have higher plasma levels of IL-6 and 
TNF-R1. Toxic look, constipation and splenomegaly may be considered as 
indicators of drug resistance.   
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METHODS 
The study included 30 children (20 males and 10 
females), of ages ranging from 3 to 13 years (X ± 
SD: 8±4.7 years), who were admitted to Zagazig 
Fever Hospital, during the year 2008. The isolate 
organism confirmed to Salmonella by stool culture 
on selenite broth6. 
Ethical approval was obtained from the local 
research ethics committee and parents of all 
subjects gave an informed written consent prior to 
the study. 
All patients were given oral chloramphenicol 
(in a dose of 100 mg/kg/day) divided every 6 hours 
and oral cotrimoxazole (in a dose of 48-60 mg 
daily) in 2 divided doses. According to the 
response to therapy, at the 5th day7, patients were 
divided into 2 groups: 
 
Group I (Responsive): Twenty patients (12 males 
and 8 females), of mean age 8±5 years who 
showed clinical improvement with treatment. 
 
Group II (Resistant): Ten patients (6 males and 4 
females), of mean age 7.75±4.2 years, who did not 
show improvement after 5 days of therapy. 
 
Ten healthy children (6 males and 4 females) 
of mean age 8.1±5.3 years were studied as control 
group. 
 
All children were subjected to the following: 
1. Clinical history taking including time of onset 
and character of fever, chills, headache, loss of 
appetite, constipation or diarrhea and abdominal 
pain  
2. Physical examination including diurnal body 
temperature measurement, heart rate, 
splenomegaly and skin rash. 
3. Routine laboratory investigations, including 
complete blood count (CBC), erythrocyte 
sedimentation rate (ESR) and C-reactive protein 
(CRP)8. The diagnosis of typhoid fever was 
confirmed by Widal test using Murex-stained 
Salmonella suspension (Dartford, UK)9, as well 
as isolation of S. typhi after stool culture, 
according to the method described by Old10. 
4. Measurement of plasma IL-6 and TNF-R1 on 
admission and on day 5 after treatment. IL-6 
measurement was done using a commercially 
available ELISA kit protocol (Cell Science, Inc. 
Catalog No. 850.030.096). The cut off level of 
IL-6 was 0.99 pg/ml. TNF-R1 measurement was 
done using PREDICTA TNF-R111. The cut off 
level of TNF-R1 was 64.0 pg/ml. 
 
Statistical analysis12 
Data were presented as mean ± standard deviation 
(X±SD) or percentage (%). The means of two 
groups were compared using student "t" test. 
Linear correlation and regression were used to test 
the correlation between the measured cytokines 
(IL-6 and TNF-R1) and some laboratory tests in all 
patients. Odds ratio was used to quantify the risk. 
Cut off values were calculated as mean ± 2SD of 
control. 
Data were carried out with the statistical package 
for Social Sciences (SPPS), version 10 software. P-




Analysis of clinical and laboratory characteristics 
revealed that toxic look, constipation, high fever, 
splenomegaly, and increased CRP and ESR were 
significantly more prevalent in children resistant to 
therapy of typhoid fever than in responsive 
children (Table 1). 
Table 2 shows that both IL-6 and TNF-R1 
plasma levels were significantly higher in patients 
than in controls and in resistant cases than in 
responsive cases both before and 5 days after 
treatment. 
Significantly higher IL-6 was noticed in 
patients after treatment, both the responsive and 
the resistant, than in controls. The same applies to 
TNF-R1 (Table 3). 
IL-6 levels correlated significantly with ESR 
values but not with S. typhi O and H titres nor 
TLC. On the other hand TNF-R1 correlated 
significantly with S. typhi H agglutination titres 
and ESR, with nonsignificant correlation with S. 
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(n = 20) 
Resistant 
Patients 
(n = 10) 
OR (95% CI) P 
Symptoms (n and %) 
Abdominal pain and anorexia 18 (90) 8 (80) 0.44 (0.03-5.58) 0.58 
Headache and malaise 11 (55) 4 (40) 0.55 (0.09-3.24) 0.43 
Chills 8 (40) 2 (20) 0.38 (0.04-2.82) 0.41 
Diarrhea 6 (30) 2 (20) 0.58 (0.06-4.62) 0.68 
Constipation  4 (20) 8 (80) 16 (1.87-180.33) 0.004* 
Toxic look 7 (35) 8 (80) 7.43 (0.98-69.99) 0.02* 
Signs  (X±SD) 
Temperature (°C) 38.6 ± 0.4 40 ± 0.6  < 0.001** 
Liver span (cm) 8 ± 2 7.5 ± 1.6  0.49 
Spleen below costal margin (cm) 1 ± 0.5 3 ± 1.  0.22 
Laboratory data  (X±SD) 
TLC (x103/mm3) 5.2 ± 1.4 6.6 ± 2.6  0.23 
ESR (mm/h) 60 ± 8.7 132.5 ± 15.1  0.02* 
CRP (mg/L) 27.5 ± 9.1 55 ± 6.8  <0.001** 
ESR: erythrocyte sedimentation rate, OR: odds ratio, CI: Confidence Interval, TLC: total leukocyte count, CRP: 
C-reactive protein, *: significant, **: Highly significant. 
 
 
Table 2. Plasma levels of interleukin-6 (IL-6) and tumor necrosis 
factor receptor-1 (TNF-R1) in all studied groups. 
Variable X ± SD P 
IL-6 (pg/ml) 
Control (n = 10) 0.57 ± 0.21 
All patients before treatment (n = 30) 6.23 ± 4.71 0.01
* 
Before treatment   
Responsive patients (n = 20) 5.05 ± 2.32 
Resistant patients (n = 10) 7.38 ± 4.10 0.039
* 
After treatment   
Responsive patients (n = 20) 2.22 ± 0.81 
Resistant patients (n = 10) 3.74 ± 0.73 0.035
* 
TNF-R1 (pg/ml)      
Control (n = 10) 35.66 ± 14.21 
All patients before treatment (n = 30) 131.50 ± 18.34 0.001
* 
Before treatment   
Responsive patients (n = 20) 81.7 ± 14.22 
Resistant patients (n = 10) 165.68 ± 17.35 0.001
* 
After treatment   
Responsive patients (n = 20) 57.92 ± 11.06 
Resistant patients (n = 10) 101.38 ± 16.03 0.01
* 
* : significant, pg: picogram. 
 
 
Table 3. Interleukin-6 (IL-6) and tumor necrosis factor receptor-1 (TNF-R1) in 
patients after treatment compared to control group. 
Patients after treatment 
(n=30) Variable Control (n=10) Responsive 
(n=20) 
Resistant 
(n=10)   
F p 
IL-6 (pg/ml) 0.57±0.21* 2.22 ±0.81 3.74±0.73 52.69 <0.001** 
TNF-R1 (pg/ml) 35.66±14.21* 57.92±11.06 101.38±16.03 66.12 <0.001** 
*: p< 0.001 when controls were compared with responsive or resistant patients. 
**: highly significant 
 
 
Ali and Abdulaziz. 
 ٥٨
Table 4. Correlation between the measured cytokines (IL-6 and TNF-R1) and some laboratory investigations 
in study patients. 
IL-6 TNF-R1 Variable 
r r 
S. typhi O agglutination titre 0.033 0.116 
S. typhi H agglutination titre 0.023 0.98* 
Total leucocytic count 0.022 -0.101 
Erythrocyte sedimentation rate 0.579* 0.643* 




In this study we classified our patients into 2 groups 
according to the clinical response to a combination 
of chloramphenicol and co-trimoxazole. 
Responders were 20 cases (66.7%) and resistant 
cases were 10 (33.3%). This response rate is similar 
to that reported by other studies13,14. Furthermore, 
Tohme et al.14 added that in spite of in vitro 
resistance, chloramphenicol and co-trimoxazole 
remain the first choice treatment of enteric fever as 
they usually achieve clinical cure in the majority of 
typhoid patients. 
In this study, toxic look, constipation, high 
fever, marked splenomegaly, and raised CRP 
significantly characterized resistant cases. The 
variation in the frequency of clinical features may 
be explained by variation in age, as infants and 
young children, for example, develop diarrhea 
rather than constipation15. Also this may be due to 
variations in endotoxin production, local 
inflammatory and/or host immune reactions 
between responsive and resistant cases16. 
In this study, resistant cases had a significantly 
higher mean ESR than patients who responded to 
drug therapy. Wyant et al.17 attributed this increase 
to increased IL-6, and considered it as one of the 
major physiological mediators of acute phase 
reaction. They confirmed this observation with 
significant positive correlations of IL-6 with fever, 
ESR and CRP. 
In our series, patients had significantly higher 
IL-6 levels, before treatment compared to controls. 
This increased level of IL-6 may be due to 
enhanced IL-6 gene expression in human 
monocytes stimulated by S. typhi proteins18. In 
addition bacterial antigen is usually recognized by 
intestinal epithelial cells via toll-like receptors to 
initiate the cellular immune responses, where 
elevated IL-6 is one of its manifestations19. 
Resistant patients had significantly higher levels of 
IL-6, before treatment, compared with responders, 
indicating a prognostic value of IL-6. This is in 
agreement with Bhutta et al.20. 
Five days after treatment, the decline of IL-6 
was significant in both responsive and resistant 
patients. This finding clarifies the inflammatory 
role of IL-6 and that it is one of the mediators 
responsible for persistence of inflammatory 
manifestations, especially in the resistant patients21. 
In this study, there was significantly higher 
TNF-R1 in all patients compared with controls. 
This was more obvious in resistant cases compared 
with responsive cases both before and 5 days after 
treatment. This agrees with Beutler et al.22 who 
reported higher levels of TNF-R1, in resistant 
typhoid patients, associated with prolonged fever or 
relapse after treatment with chloramphenicol, when 
compared with responsive patients. They concluded 
that such higher levels of TNF-R1 may be capable 
of binding TNF and thus enhancing its harmful 
effects. It is to be noted that the levels of TNF-R1 
declined significantly after 5 days of treatment. 
This agrees with the findings of Wyant et al.17 who 
found that stimulation with Salmonella typhi 
flagella has induced rapid de novo synthesis of 
TNF-R1, during acute typhoid illness which 
decreased with convalescence. 
Upon correlation of studied cytokines and some 
laboratory data, we found significant positive 
correlation of IL-6 with ESR (r = 0.579). This result 
was in agreement with Zherebtsova et al.23 who 
found medium positive relationship between the 
level of IL-6 and changes in blood including ESR. 
Also our study showed significant positive 
correlations of TNF-R1 with S. typhi H 
agglutination titre and with ESR which may reflect 
the positive activities of these cytokines24. 
In conclusion, the studied children with typhoid 
fever who were resistant to treatment with 
chloramphenicol and co-trimoxazole had higher 
levels of IL-6 and TNF-R1 than those who were 
responsive. Toxic look, constipation and 
splenomegaly may be considered as indicators of 
drug resistance. IL-6 and TNF-R1 have a role in the 
pathogenesis of typhoid fever and we recommend 
further studies to define the exact role of 
immunomodulation in treating resistant cases. 
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